Developing a potential drug candidate is an iterative process that requires careful planning to reach clinical trials. Most new drug candidates fail during preclinical and clinical development, and identifying those with promising ADME and pharmacokinetics properties during the discovery stage can streamline the development process. Preclinical ADME screening, drug metabolism, and pharmacokinetics assessments focus effort on potentially viable drug candidates, guiding decision-making from early discovery to Investigational New Drug (IND) filing and beyond.
As an industry leader clinical trial laboratory services, Q2 Solutions can help you make informed development decisions about your drug candidates by offering an array of high-throughput ADME screening and DMPK services that use validated bioanalytical methods to support candidate identification and characterization. Our scientists have extensive expertise with high-throughput discovery bioanalysis and LC/MS bioanalysis platforms that enable various aspects of ADME testing and pharmacokinetic (PK) testing. From in vitro ADME screening assays and drug-drug interaction risk assessment to metabolite identification of in vitro and in vivo samples, Q2 Solutions’ services facilitate rapid drug discovery ADME property optimization and regulatory filings.